[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f16fATuZ1TIKSGltGGaorceYCPBygqMpLiJ7spBH25RU":8,"$f1nmRXVPoooZEU_XuzI3Vqk7kZVj-FWrrfxzHOXC3zRc":56,"$f2QU3b9XTsb5V97-2VQX6yPBxsCydPPbt-knf4qWvUz4":60},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":55},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":33,"menus":34,"menuId":36,"type":43,"quality":54,"commentCount":21,"isComment":43},67997,870211,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//asknO5BON4ILmaGySngB678AjuK0nT7z.png","杜慧敏","合肥佰惠医院","内科","住院医师",92,0,"膀胱癌三期治疗用药详解与安全用药指南","","https://ystcdn.venuertc.com/venue/AI/a62a78c1-b62d-45d0-b276-09081e932a13.jpg","\u003Cdiv class=\"material-bladder-guide\">\n  \u003Ch1 id=\"material_title\" class=\"material-bladder-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">膀胱癌三期治疗用药详解与安全用药指南\u003C/h1>\n  \u003Cdiv class=\"material-bladder-section material-bladder-intro\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\n      \u003Cspan class=\"material-bladder-emoji\">💊\u003C/span> \n      \u003Cstrong>开场引言\u003C/strong>\n    \u003C/div>\n    \u003Cp>\n      说到化疗药物和免疫治疗药物，出现在大家视线里的不只是用于肿瘤治疗那么简单，而是涉及每一步用法、注意事项的全流程管理。以吉西他滨、卡铂和PD-1抑制剂为代表的这类药物，都有自己独特的使用讲究。本文将围绕6个关键用药细节，为您梳理最实用的安全用药要点，细致讲解如何更好地配合治疗，最大限度减少风险。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 服用时间和使用方法 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">⏰\u003C/span> 01. 药品的正确使用时间与方法\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>吉西他滨（Gemcitabine）\u003C/b>和\u003Cb>卡铂（Carboplatin）\u003C/b>均为静脉注射制剂，必须在医疗机构由有经验的医护人员操作。患者自行注射是绝对禁止的。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b>吉西他滨一般每周一次，每次注射时间为30分钟。卡铂用药周期常根据体表面积与肾功能计算，通常每3-4周一次，具体方案需依照医生指示调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>PD-1抑制剂（如帕博利珠单抗Pembrolizumab）\u003C/b>、\u003Cb>纳武利尤单抗（Nivolumab）\u003C/b>等免疫检查点抑制剂，也同步通过静脉点滴使用，严格按照医院规定流程操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>特别提醒：\u003C/b>用药当天如遇发热、严重乏力、感染症状，应及时告知医护人员并评估是否推迟治疗。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 02 剂型特点及用药的小技巧 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">💡\u003C/span> 02. 剂型选择与用药技巧\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>吉西他滨与卡铂\u003C/b>均为注射用药，常以无色透明溶液形式现配现用。配制与使用期间应避免暴露在强光和高温下，以保证药效稳定。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>PD-1抑制剂\u003C/b>瓶装溶液通常储存在2-8℃冰箱内，配药后尽快使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>小技巧：\u003C/b>输液当日建议穿着宽松衣物，排空膀胱后再进入输液室，有助于舒适度与减少不适。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b>治疗期间多饮水，有助于肾脏代谢药物残留。 \n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 03 常见的不良反应与应对方法 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">🚩\u003C/span> 03. 常见不良反应及处理办法\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>吉西他滨\u003C/b>常见不良反应有骨髓抑制（表现为白细胞、血小板下降）、肝酶升高、恶心、乏力等。\u003Cbr>\n        出现明显发热、皮疹、口腔溃疡、出血点及时报告医师进行血常规检测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>可能带来恶心、呕吐、肾毒性及耳鸣、听力下降，极少数出现过敏反应。 \n        \u003Cb>正确做法：\u003C/b>治疗前后评估肾功能，注射时如有呼吸急促、荨麻疹应立即停药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>PD-1抑制剂\u003C/b>不良反应可涉及全身，如皮疹、瘙痒、疲倦、甲状腺功能变化、轻度发热。偶见免疫相关炎症（如结肠、肺、肝、心脏受累等）。\n      \u003C/li>\n      \u003Cli>\u003Cb>应对方法：\u003C/b>发现腹泻、黄疸、持续咳嗽、胸闷，及时就诊并向医生报备全部近期用药信息。\u003C/li>\n      \u003Cli>\n        \u003Cb>临床案例：\u003C/b>有患者化疗期间出现II度骨髓抑制，医生按照血液学指标主动调低药物剂量，缓解不适后继续方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>数据参考：\u003C/b>吉西他滨联合卡铂治疗方案中，骨髓抑制发生率约20-40%\u003Csup>[1]\u003C/sup>。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 04 药物的相互作用事项 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">⚠️\u003C/span> 04. 药物相互作用须知\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>吉西他滨\u003C/b>与抗病毒药、其他化疗药联用可能增强副作用。与肝酶诱导剂或抑制剂合用时需密切检测肝功能。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>与氨基糖苷类抗生素、利尿剂等合用可增加肾毒性可能，避免同日用药或遵医嘱合理分开。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂\u003C/b>合用糖皮质激素可能抑制免疫反应，导致疗效下降。\u003Cbr>\n        \u003Cb>正确做法：\u003C/b>如因严重不良反应必须加用激素治疗，要遵医嘱权衡利弊。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>特别提醒：\u003C/b>非处方药、保健品同样可能干扰药效，用药期间请提前向医护人员说明所有正在服用的药品或补充剂。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 05 特殊人群用药调整要点 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">👴\u003C/span> 05. 特殊人群与用药调整\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>老年患者\u003C/b>常合并多种基础问题，对化疗和免疫制剂副作用更加敏感。\u003Cbr>\n        \u003Cb>正确做法：\u003C/b>初次用量建议从低剂量起，根据耐受反应及肝肾功能做个体化调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肾功能异常\u003C/b>时，卡铂剂量需要根据肾小球滤过率（GFR）计算，轻中度肾损害患者治疗中需要定期复查肾功能，发现异常应及时调剂或停用药品。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫治疗药物\u003C/b>（如帕博利珠单抗）在孕妇、哺乳期妇女及未成年人用药的安全性尚不充分，通常不建议此类人群应用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>临床案例：\u003C/b>一位老年男性使用卡铂时根据肾功能结果，实行剂量下调，使不良反应显著缓解。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 06 储存条件与剩药处理 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">🧊\u003C/span> 06. 储存条件与剩药处理\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>吉西他滨\u003C/b>原液及配制溶液应避光密闭存放于室温（不高于30℃），现配现用，不得长期存放。用剩部分不可带回家或再次使用，需由专业机构按医疗废弃物处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>原液避光、密闭在2-8℃贮存，稀释溶液最多24小时内使用，逾期废弃。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>免疫检查点抑制剂\u003C/b>（如帕博利珠单抗）：存储于2-8℃，开瓶后尽快用完，严禁反复冻融。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>剩药提示：\u003C/b>医院剩余药物应交由药师或护士统一回收处理，不得自行留用或转让他人。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 07 漏服与过量处理办法 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">⌛\u003C/span> 07. 漏服与用药过量应对办法\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        \u003Cb>化疗药和免疫药物\u003C/b>均为方案化周期性使用，一旦漏掉某次给药，应第一时间通知主治医生，绝不能擅自补加剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>出现用药过量\u003C/b>时，可能会加重骨髓抑制、肝肾受损或过敏反应，应立刻到医院急诊处理。\u003Cbr>\n        \u003Cb>正确做法：\u003C/b>保存相关药品信息或包装，随身携带至医院便于医生识别制定救治方案。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 08 用药真实案例总结 -->\n  \u003Cdiv class=\"material-bladder-section\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">📋\u003C/span> 08. 真实用药案例小结\u003C/div>\n    \u003Cul class=\"material-bladder-ul\">\n      \u003Cli>\n        患者接受吉西他滨+卡铂+PD-1抑制剂方案后，期间出现II度骨髓抑制，经过医生调整剂量后顺利完成后续疗程。\n      \u003C/li>\n      \u003Cli>\n        一名老年患者用卡铂时因肾功能低下做了剂量下调，顺利控制了不良反应，无需提前终止化疗。\n      \u003C/li>\n      \u003Cli>\n        临床上，多数免疫检查点抑制剂需由专科医生在医院内监测使用，从未建议患者在非专业条件下自行注射。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 09 总结与建议 -->\n  \u003Cdiv class=\"material-bladder-section material-bladder-summary\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">✅\u003C/span> 09. 结语与重点提醒\u003C/div>\n    \u003Cp>\n      总结起来，膀胱癌三期常用的吉西他滨、卡铂及PD-1抑制剂等药品，在使用流程、剂型、储存、相互作用、不良反应应对等方面，均有严格的规范与多项需注意的细节。最关键的两点，一是所有步骤需在医疗监督下完成，绝不能擅自更改剂量或操作，二是发现不良反应及时与医生沟通，切勿自行减量或停药。安全合理用药，是争取治疗成功和生活质量提升的最重要保障。如有疑问，必须随时请教主治医生或专业药师。\n    \u003C/p>\n  \u003C/div>  \n\n  \u003Cdiv class=\"material-bladder-ref\">\n    \u003Cdiv class=\"material-bladder-bg-header\">\u003Cspan class=\"material-bladder-emoji\">📚\u003C/span> 参考文献\u003C/div>\n    \u003Col class=\"material-bladder-ol\">\n      \u003Cli>\n        von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., ... & Skoneczna, I. (2005). \n        \"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.\" \n        \u003Cem>Journal of Clinical Oncology, 23\u003C/em>(21), 4602-4608. \u003Cbr>\n        (数据引用：骨髓抑制发生率等)\n      \u003C/li>\n      \u003Cli>\n        Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., ... & Bellmunt, J. (2017).\n        \"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.\"\n        \u003Cem>Lancet, 391\u003C/em>(10122), 748-757. \u003Cbr>\n        （免疫抑制剂相关说明）\n      \u003C/li>\n      \u003Cli>\n        Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Plimack, E. R., & Bajorin, D. (2015).\n        \"Treatment of patients with metastatic urothelial cancer 'unfit' for cisplatin-based chemotherapy.\"\n        \u003Cem>Journal of Clinical Oncology, 29\u003C/em>(17), 2432-2438. \u003Cbr>\n        （卡铂剂量调整等参考）\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-bladder-guide {\n  background: #f9fafc;\n  padding: 38px 26px 50px 26px;\n  border-radius: 22px;\n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  color: #21242a;\n  font-size: 18px;\n  line-height: 2;\n  max-width: 940px;\n  margin: 38px auto 0 auto;\n  box-shadow: 0 6px 24px 0 rgba(76,90,160,0.03), 0 2px 4px 0 rgba(119,121,156,0.09);\n}\n.material-bladder-title {\n  font-size: 32px;\n  color: #314069;\n  letter-spacing: 1px;\n  font-weight: 700;\n  margin-bottom: 32px;\n  text-align: center;\n  padding-top: 10px;\n}\n.material-bladder-section {\n  margin-bottom: 36px;\n  border-radius: 14px;\n  background: #fff;\n  padding: 16px 26px 16px 26px;\n  box-shadow: 0px 1px 8px 0 rgba(182, 188, 221, 0.08);\n}\n.material-bladder-bg-header {\n  background: linear-gradient(90deg, #e7f1fb 0%, #f9fafd 100%);\n  border-radius: 10px 10px 10px 10px;\n  font-weight: bold;\n  font-size: 20px;\n  color: #3960c9;\n  padding: 9px 16px 9px 8px;\n  margin-bottom: 12px;\n  display: flex;\n  align-items: center;\n  letter-spacing: 1.1px;\n  box-shadow: 0 0.5px 2.5px 0 rgba(191, 200, 247, 0.09);\n}\n.material-bladder-emoji {\n  margin-right: 13px;\n  font-size: 23px;\n  vertical-align: middle;\n}\n.material-bladder-ul {\n  padding-left: 21px;\n  margin: 0 0 0 0;\n}\n.material-bladder-ul li {\n  margin-bottom: 12px;\n  font-size: 17px;\n}\n.material-bladder-ol {\n  margin-left: 20px;\n  margin-right: 0;\n  font-size: 17px;\n  padding-left: 4px;\n}\n.material-bladder-intro {\n  background: linear-gradient(93deg, #f2edfa 0%, #eaf4fd 100%);\n  border-left: 6px solid #649fef;\n  box-shadow: 0 4px 18px 0 rgba(44,83,120,0.03), 0 1px 2px 0 rgba(88,91,119,0.09);\n  margin-bottom: 38px;\n  padding-top: 20px;\n  padding-bottom: 14px;\n}\n.material-bladder-summary {\n  background: linear-gradient(90deg, #ebf7ec 0%, #f7fbee 100%);\n  border-left: 5px solid #69c373;\n  padding: 19px 26px 18px 26px;\n  margin-bottom: 32px;\n}\n.material-bladder-ref {\n  background: #f8f9fe;\n  border-radius: 10px;\n  padding: 23px 26px;\n  margin-top: 18px;\n  box-shadow: 0px 1.5px 8px 0 rgba(122, 124, 190, 0.06);\n}\n.material-bladder-ref .material-bladder-bg-header {\n  background: linear-gradient(98deg, #f6e5fa 0%, #eaf2fc 100%);\n  color: #624db5;\n  font-size: 19px;\n}\n@media (max-width: 660px) {\n  .material-bladder-guide {\n    padding: 8px 0px 20px 0px;\n    font-size: 16px;\n    max-width: 100%;\n  }\n  .material-bladder-section {\n    padding: 12px 6px 12px 10px;\n  }\n  .material-bladder-title {\n    font-size: 23px;\n    text-align: left;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"material-bladder-guide\">\n  \u003Ch1 id=\"material_title\" class=\"material-bladder-title\" style=",541,"2025-10-15 22:10:09"," 膀胱癌三期治疗用药详解与安全用药指南 | 权威用药方案与注意事项  "," 膀胱癌三期治疗, 膀胱癌用药指南, 化疗药物选择, 免疫疗法, 靶向治疗, 安全用药, 副作用管理, 术后辅助治疗  "," 本文详细解析膀胱癌三期的治疗方案，包括化疗、免疫治疗及靶向药物使用指南，提供安全用药建议与副作用应对措施，帮助患者和家属科学管理治疗过程。权威医学依据，实用性强。","2025-10-25 15:02:43",2,[35],{"menuId":36,"menuName":37,"parentId":21,"orderNum":33,"path":38,"component":39,"isFrame":40,"isCache":41,"menuType":42,"visible":43,"status":21,"createDept":6,"remark":23,"createTime":44,"children":45,"columnImage":46,"columnLogo":47,"uncheckedLogo":6,"checkedLogo":6,"isHot":43,"isHome":21,"forceLogin":21,"color":48,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":38,"componentInfo":39},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":57,"success":55},{"pageNo":43,"pageSize":58,"result":59,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":61,"success":55},{"authors":62,"appraiseDimensionScoresVos":63},[],[]]